Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mytrex Health TechnologiesROCO:4431 +2.06%64 FCF Yield % is 30.72 as of Jul. 18, 2026, which is 1021% above its 10-year median of 2.74. GuruFocus rates ROCO:4431 with a GF Score™ of 64/100 and a GF Value™ of NT$37.17 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 3,065 Industrial Products companies, Mytrex Health Technologies ranks better than 98.21% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Mytrex Health Technologies FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Mytrex Health Technologies FCF Yield % Related Terms
Mytrex Health Technologies FCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Specialty Industrial Machinery subindustry, Mytrex Health Technologies's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mytrex Health Technologies FCF Yield % vs Industrial Products Industry
For the Industrial Products industry and Industrials sector, Mytrex Health Technologies's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Mytrex Health Technologies's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mytrex Health Technologies (ROCO:4431) has a FCF Yield % of 30.72 as of Jul. 18, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Mytrex Health Technologies and its competitors. This is 1021% above median its historical median of 2.74. According to the industry distribution chart, Mytrex Health Technologies ranks #55 out of 3065 companies in the Industrial Products industry, placing it in the top 1.8%.
Is Mytrex Health Technologies' FCF Yield % too high?
Mytrex Health Technologies' current FCF Yield % of 30.72 is 1021% above median its 10-year median of 2.74. The Industrial Products industry median FCF Yield % is 0.61. Mytrex Health Technologies' value of 30.72 is 4936.1% above this industry median. Based on the distribution chart, Mytrex Health Technologies ranks #55 out of 3065 companies in the Industrial Products industry, which is in the top quartile — a strong position relative to peers. Overall, Mytrex Health Technologies has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Mytrex Health Technologies' FCF Yield % compare to GEV and ETN?
According to the Industrial Products industry distribution chart, Mytrex Health Technologies ranks #55 out of 3065 companies for FCF Yield %. This places Mytrex Health Technologies in the top 2% of its industry — outperforming the majority of peers. The industry median FCF Yield % is 0.61. Mytrex Health Technologies' value of 30.72 is 4936.1% above this benchmark. While the company's 10-year median is 2.74 vs. the industry median of 0.61, Mytrex Health Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for an Industrial Products company?
The median FCF Yield % among Industrial Products companies is 0.61, based on 3,065 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mytrex Health Technologies's current FCF Yield % of 30.72 is 4936.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Mytrex Health Technologies and its competitors. For the Industrial Products industry, the median FCF Yield % is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mytrex Health Technologies's current FCF Yield % is 30.72, which is 1021% above median its own 10-year median of 2.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mytrex Health Technologies stock overvalued right now?
Based on GuruFocus' analysis, Mytrex Health Technologies (ROCO:4431) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$37.17, compared to a current price of NT$17.35 — trading 53.3% below its estimated fair value. The current FCF Yield % is 30.72, which is 1021% above median its 10-year median of 2.74 and 4936.1% above the Industrial Products industry median of 0.61. Mytrex Health Technologies' overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Mytrex Health Technologies (ROCO:4431), the current FCF Yield % is 30.72 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mytrex Health Technologies (ROCO:4431) Overvalued in 2026?
Based on GuruFocus' analysis, Mytrex Health Technologies stock appears to be undervalued.
The current stock price of NT$17.35 is trading 53.3% below its estimated GF Value™ of NT$37.17.
GuruFocus considers Mytrex Health Technologies to be Significantly Undervalued.
Key valuation signals for ROCO:4431:
FCF Yield %: 30.72 (1021% above median its 10-year median of 2.74)
GF Value™: NT$37.17 vs. price of NT$17.35 (53.3% below fair value)
Industry Position: 4936.1% above the Industrial Products median (#55 of 3065)
No single metric tells the full story. See the ROCO:4431 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mytrex Health Technologies Inc is a Taiwan-based company engaged in the manufacturing of non-woven materials and special medical supplies. It is engaged in the development and production of melt-blown products for the protection of the environment and human health. The company offers products ranging from medical to industrial filtration materials such as various types of filtration media, lab coats or outfits, cabin filtration, vacuum cleaner filter bags, and special medical supplies. Its product categories include meltdown, mammoth bedding, and specialized medical supplies like balloon catheters and coronary stents.
64GF Score
Get the complete analysis for ROCO:4431
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4431 has been successfully added to your 
